Docket Management
Docket: 00N-1256 - Over-the-Counter Products
Comment Number: EC -65

Accepted - Volume 6

Comment Record
Commentor Ms. Nancy Gonzalez-Caro, MPH Date/Time 2000-06-28 17:10:24
Organization Ms. Nancy Gonzalez-Caro, MPH
Category Individual

Comments for FDA General
Questions
1. General Comments I learned on the news last night of your hearings on over-the counter products. I also read this morning that my health insurer Blue Cross is encouraging consideration of moving Claritin to OTC. I wish to say that I do not think that profits should make this decision. Consumers have a hard enough time figuring out which medicines to take and for what as it is. There are significant side effects to watch for with allergies and high cholesterol. They are trying to shift the cost of medicines to consumers and keep their profits high. Do not fall for these tactics. I urge you to consider deciding for consumers and not profits for health care insurers and drug companies.




EC -65